AFYX Therapeutics today touted results from a study exploring the delivery of antibody fragments using the company’s Rivelin technology.
The preclinical study, conducted in collaboration with the University of Sheffield in the United Kingdom, evaluated Rivelin for delivering the antibody fragments directly to inflamed tissue in mucosal diseases.
Get the full story at our sister site, Drug Delivery Business News.